Run time: 62m

  0      0

2019 AABB Annual Meeting On-Demand


TU1-04: HLA Epitope Matching: Towards Precision Medicine in Transfusion and Transplantation


Oct 22, 2019 7:00am ‐ Oct 22, 2019 8:30am

Expiration Date: Dec 31, 2021


Credits: None available.

Standard: $25.00
Members: $20.00

Description

Human leukocyte antigens (HLA) are highly polymorphic tissue antigens that constitute the major immunologic barrier to platelet transfusion and transplantations. Antibodies that recognize mismatched epitopes on HLA molecules are the primary cause of platelet refractoriness and transplant rejection. The traditional approach to HLA matching at the antigen or allele level does not capture the full picture of HLA disparity at the epitope level. 

Recent clinical studies have highlighted the benefit of using epitope-based HLA matching to guide platelet product selection and to risk stratify patients undergoing allogeneic transplantations. In this session, we will first introduce the concept and process of HLA epitope matching, followed by a critical review of the evidence for epitope-based matching for platelet transfusion in HLA-alloimmunized patients. Next, we will present the current understanding of the role of epitope mismatch in the development of de novo donor-specific HLA antibodies after kidney transplantation. We will also discuss the potential of optimizing the transplant outcome by considering epitope matching in kidney allocation and personalized immune suppression. Finally, we will discuss the differential impact of epitope mismatch directed toward the graft or host in haploidentical hematopoietic stem cell transplantation.

Learning Objectives:

  • List the key elements of human leukocyte antigen (HLA) epitope matching.
  • Evaluate the evidence for epitope-based approach to platelet transfusion refractoriness.
  • Incorporate epitope matching into the risk stratification of patients undergoing kidney and hematopoietic stem cell transplantations.

Please note: Chang Liu, MD, PhD did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):

Disclosures

  • Mark Fung, MD PhD :

    Cerus Corporation: Consultant  I  Grifols Corporation: Honoraria

  • Chang Liu, MD, PhD :

    Nothing to Disclose

  • Peter Nickerson, MD, FRCPC, FCAHS :

    Vitaeris Inc: Consultant  I  National Institutes of Health: Grant/Research Support (Secondary Investigators need not disclose)  I  Viela Bio Inc: Consultant  I  Astellas Pharma Taiwan Inc.: Honoraria  I  Astellas Pharma China Inc.: Honoraria

Credits Available


TU1-04: HLA Epitope Matching: Towards Precision Medicine in Transfusion and Transplantation Evaluation

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content